Introduction
============

Background
----------

Older adults with a range of comorbidities are often prescribed multiple medications, some of which may impact on their function and cognition, and many have a potential for drug interactions.[@b1-cia-9-1453] Studies showing evidence of benefit from pharmacotherapy have mostly been conducted in younger patients, and it is unclear how this translates to frail older patients. These patients are often excluded from drug trials; yet they are the largest consumers of medications.[@b1-cia-9-1453] Several studies have found current use of five or more drugs in well over a quarter of older community dwelling adults,[@b2-cia-9-1453]--[@b4-cia-9-1453] with higher prevalence in frail older populations and in hospitalized patients.[@b5-cia-9-1453],[@b6-cia-9-1453]

The assessment of frailty using various methods, including the Frailty Index, is being incorporated in recent studies of older adults and provides an insight into their accumulated deficits and reduced reserve.[@b7-cia-9-1453],[@b8-cia-9-1453] The increased number of comorbidities requiring medications makes these patients prone to polypharmacy, yet their frailty status, together with the pharmacokinetic and pharmacodynamic changes that occur with aging, places them at risk of adverse events. The risks of polypharmacy include non-adherence, adverse drug reactions, drug--drug interactions, falls, fractures, poor nutrition, and mortality,[@b9-cia-9-1453]--[@b14-cia-9-1453] as well as increased exposure to potentially inappropriate medications (PIMs).[@b5-cia-9-1453],[@b15-cia-9-1453] However, few studies have reported on the association of polypharmacy with functional outcomes in older patients.

Aims
----

The aims of the study were to

1.  Explore the extent of polypharmacy in a cohort of older patients discharged from hospital to a home care program;

2.  Assess the relationship between polypharmacy and patient characteristics, functional outcomes, and frailty; and

3.  Describe the prevalence of the most common medications in this cohort, with particular emphasis on PIMs.

Methods
=======

Study design, setting, and participants
---------------------------------------

A prospective observational cohort study of older persons discharged from hospital to a community-based Transition Care Program was conducted at six sites in two Australian states, Queensland and South Australia. The Transition Care Program (TCP) is designed to facilitate transitions from hospital to home for older people (aged 70 years and over or 50 years and over for the indigenous population), offering those with high care needs additional support during convalescence.[@b16-cia-9-1453] The program is therapy focused, providing a package of services which includes home help and personal care, physiotherapy and occupational therapy, nursing care, and case management over a maximum period of 12 weeks (average 7 weeks) post-discharge from hospital.[@b16-cia-9-1453] The provision of primary medical care to a Transition Care recipient is undertaken by their general practitioner.[@b16-cia-9-1453]

Consecutive patients entering the TCP during the period from November 2009 to September 2010, who gave informed consent to participate, were eligible for the study. Recruitment details for the study, originally designed to examine the functional recovery trajectories of patients with high care needs, have previously been published.[@b17-cia-9-1453] Ethics approval was given by the University of Queensland Human Research Ethics Committee (HREC) as well as HRECs responsible for governance at each of the TCP sites.

Data collection
---------------

A comprehensive geriatric assessment using the interRAI Home Care instrument was conducted at TCP admission and discharge. The interRAI instruments comprise a suite of assessment tools to support assessment and care planning of persons with chronic illness, frailty, and disability across care settings,[@b18-cia-9-1453] with substantial reliability on core items in common.[@b19-cia-9-1453] The interRAI Home Care assessment collects data on multiple domains including sociodemographics, medical conditions, medications, physical and mental function, nutrition, and symptoms and syndromes such as mood, behavior, and continence. A number of scales embedded in the interRAI instruments combine single items belonging to a domain, such as activities of daily living (ADL), instrumental ADL (IADL), and cognition, which can be used to describe the presence and extent of deficits in that domain.[@b17-cia-9-1453],[@b20-cia-9-1453],[@b21-cia-9-1453] Trained assessors gathered data from multiple sources including from the patient, carers, medical and allied health staff, and hospital records. Medications from hospital discharge summaries were coded by pharmacy students using the World Health Organization Anatomical Therapeutic Chemical (ATC) Classification System and reviewed by a pharmacist and a geriatrician.

Measures
--------

### Medication exposure

There is no universally accepted definition of polypharmacy in the literature. Some studies define it as use of five or more medications.[@b2-cia-9-1453]--[@b4-cia-9-1453],[@b11-cia-9-1453] This has been supported in a recent study investigating polypharmacy cutoff points and risks of adverse outcome.[@b22-cia-9-1453] Moreover, recent studies have defined the use of ten or more medications as excessive polypharmacy[@b10-cia-9-1453],[@b23-cia-9-1453] or hyperpolypharmacy.[@b24-cia-9-1453] Inclusion of over-the-counter medications and medications not consumed on a regular basis is also variable. In our study, polypharmacy status was categorized into three groups -- non-polypharmacy (0--4 drugs), polypharmacy (5--9 drugs), and hyperpolypharmacy (≥10 drugs) -- based on regular medications. Drugs, vitamins, and mineral supplements administered on a regular basis through any recognized drug-delivery method were included in the analysis. Supplements without ATC codes, such as cranberry juice and primrose oil, were excluded.

The American Geriatrics Society 2012 Beers Criteria was used to identify PIMs with a recommendation to avoid, regardless of patients' comorbidities. We included as PIMs those medications where the recommendation to avoid was strong and the quality of evidence was classified as moderate or high, also taking into account exposure to drugs above recommended maximum daily dose.[@b25-cia-9-1453] [Table S1](#SD1-cia-9-1453){ref-type="supplementary-material"} lists the PIMs meeting these criteria.

### Frailty

The frailty index (FI) was calculated using a well described methodology,[@b26-cia-9-1453] based on accumulated health deficits such as symptoms, signs, disabilities, and diseases measured in the interRAI Home Care assessment. Disability in ADL and IADL, impairments in general cognition and mobility, number of comorbidities, incontinence, and depressed mood were included as deficits. For each patient, deficits were added and divided by the total counted, here 57, to calculate an individual index score. Polypharmacy was excluded from the deficit count. The higher the score, the greater the number of deficits, and the more likely the patient is to be frail. In community-dwelling older people, 0.25 has been proposed as the cutoff between "fit" and "frail," with scores of \>0.40 associated with dependence on others for activities of daily living.[@b27-cia-9-1453]

Analysis
--------

To describe characteristics across polypharmacy groups, comparison of means (analysis of variance) or medians (Kruskal--Wallis test) for continuous variables was used, depending on distribution of the data. For categorical variables, chi-square or Fisher's exact test (where cell numbers are less than five) was performed. An exploratory analysis using logistic regression models tested the association between polypharmacy, frailty status, and functional outcomes. For the purpose of interpreting odds ratios, FI was multiplied by 10 so that the per-unit change was 0.1.[@b8-cia-9-1453] Patients with missing data were excluded from the relevant analysis, and percentages were reported as proportions of patients with available data. Significance level was set at *P*-value of \<0.05. The SPSS IBM version 22 was used for analysis.

Results
=======

Of the 351 TCP clients enrolled in the study, four cases had missing medication data. The remaining 347 cases were included in the analysis. The mean age (standard deviation \[SD\]) was 78.9 (±8.8) years, and 65.7% were females. The majority of patients discharged to the TCP needed ongoing support after hospitalization for orthopedic conditions (50.7%), including fractures (37.5%), medical conditions resulting in deconditioning (23.6%), and stroke (14.6%). The median length of stay in the TCP was 54 days (interquartile range 37--73 days).

The number of regular medications taken ranged from 0 to 24, with a mean (SD) of 8.5 (±3.6). For "as needed" pro re nata (PRN) medications, the mean (SD) was 0.8 (±1.1). Only 14.1% of patients took \<5 regular medications (non-polypharmacy). Polypharmacy (5--9 drugs) was observed in 46.7% and hyperpolypharmacy (≥10 drugs) in 39.2%. The majority in the hyperpolypharmacy group (n=131; 96.3%) were taking between 10 and 15 regular medications, with five taking more than 15 regular medications.

[Table 1](#t1-cia-9-1453){ref-type="table"} shows the characteristics of patients according to polypharmacy categories at admission to the TCP. Patients with polypharmacy and hyperpolypharmacy had more comorbidities than the non-polypharmacy group and were more likely to have diabetes mellitus, coronary heart disease, chronic obstructive pulmonary disease (COPD), or depression. They were also more likely to have symptoms of pain, dizziness, and dyspnea. There was no significant association between polypharmacy categories and stroke, congestive heart disease, Parkinson's disease, or cancer. Considering frailty status and geriatric syndromes (including history of falls in the previous 90 days, impaired cognition, dependence in basic and instrumental ADL, and bladder incontinence), only the FI had a significant association with polypharmacy.

[Table 2](#t2-cia-9-1453){ref-type="table"} shows outcomes at discharge from the TCP according to polypharmacy status. The majority of patients continued living in the community (85.6%), 12.4% were readmitted to hospital, 0.9% were discharged to residential aged care facilities (RACF), and 1.2% died. Patients in the polypharmacy and hyperpolypharmacy groups were more likely than the non-polypharmacy group to fail to improve in ADL and IADL and were more likely to fall over the duration of the TCP.

Multivariate models of functional outcomes (failure to improve ADL or IADL or falls over the TCP), with FI and polypharmacy groups as covariates, show that frailty status mediates the effects of polypharmacy. The odds ratios of ADL and IADL functional decline and falls for a 0.1 increase in FI are shown in [Table 3](#t3-cia-9-1453){ref-type="table"}.

[Table 4](#t4-cia-9-1453){ref-type="table"} shows the most common drug categories by polypharmacy group. The most commonly used drugs were analgesics (56.8%). Non-opioid drugs were prescribed more frequently than opioids (46.1% and 27.1%, respectively). Anti-ulcer drugs (52.7%), statins (44.1%), aspirin, and anti-aggregates (43.2%) followed. Cardiovascular drugs were also commonly used. Beta blockers and angiotensin converting enzyme inhibitors were each prescribed in about a third of patients, while diuretics, calcium channel blockers, and angiotensin receptor blockers were each prescribed in about a quarter of the patients. Vitamin D and analogues were prescribed in 27.1%, while anti-resorptives and calcium were taken by 22.5% and 24.5%, respectively. A high proportion was prescribed antidepressants (30.8%) and laxatives (28%). Only nine patients were on antipsychotics and four patients on anti-dementia drugs. In all but a few drug categories (anticoagulants, oral hypoglycemics, anti-emetics, anti-Parkinson, antipsychotics, and anti-dementia drugs) the prevalence of each drug class increased significantly across the polypharmacy groups, with the hyperpolypharmacy group having the highest prevalence.

The number of TCP patients taking at least one PIM was 41 (11.8%), with two persons taking two PIMs. Of those taking at least one PIM, 2 (4.1%) were in the non-polypharmacy group; 17 (10.5%) were in the polypharmacy group; and 22 (16.2%) in the hyperpolypharmacy group. This distribution failed to reach statistical significance (*P*=0.066; Fisher's exact test). The commonest PIMs prescribed were tertiary tricyclic antidepressants (9.5%), particularly amitriptyline. Digoxin at a dose of \>125 μg was prescribed in less than 2% of patients. Dipyridamol, promethazine, glibenclamide, and oral estrogens were each prescribed in only one or two patients. None of the patients was prescribed potent non-steroidal anti-inflammatory drugs which increase the risk of gastrointestinal bleeding and peptic ulceration. There were no patients on barbiturates or the antiparkinsonian agent, benztropine.

Discussion
==========

The findings of this study showed that polypharmacy was significantly associated with frailty and poor functional outcomes. However, multivariate models of functional outcomes (failure to improve ADL or IADL or falls over the TCP), with FI and polypharmacy groups as covariates, show that frailty status mediates the effects of polypharmacy. This accords with previous findings which indicate that older adults who are frail are more likely to be exposed to multiple medications associated with increases in number of comorbidities. Conversely, multiple medications may exacerbate frailty.[@b24-cia-9-1453] While the association of polypharmacy with frailty and adverse outcomes has been shown in studies of community-dwelling older adults,[@b22-cia-9-1453],[@b24-cia-9-1453],[@b28-cia-9-1453] there have been few studies which have shown this relationship in the post-acute care setting.

The majority of patients in our study (86%) were prescribed five or more medications per day. The mean number of drugs of 8.5 is higher than that reported in other studies of nursing home patients, community-dwellers, and day hospital patients, which report values of 3.7--7.9.[@b4-cia-9-1453],[@b10-cia-9-1453],[@b29-cia-9-1453]--[@b31-cia-9-1453] The definition of polypharmacy and inclusion of vitamins, minerals, and over-the-counter medications was variable in these other studies, making comparison difficult.

Similar to previous reports,[@b23-cia-9-1453],[@b32-cia-9-1453] prevalence of diabetes mellitus, coronary heart disease, COPD, and depression were lower in the non-polypharmacy group, as were symptoms of dizziness and dyspnea. In contrast to a previous study,[@b23-cia-9-1453] measures of ADL, IADL, and cognition were not associated with polypharmacy at admission to the TCP. However, better functional outcomes in ADL and IADL were achieved with TCP rehabilitation for those on fewer medications. This was most likely because of their lower levels of frailty, which is a predictor of functional gain in rehabilitation patients.[@b8-cia-9-1453] Those with fewer medications were less likely to fall over the duration of the TCP, which is consistent with studies showing a relationship between polypharmacy and risk of falls.[@b33-cia-9-1453] A strong association between cognitive impairment and reduced rates of excessive polypharmacy has recently been described in nursing-home residents.[@b23-cia-9-1453] In contrast, our study did not find such an association, most likely due to the small number of patients with severe cognitive impairment.

Analgesics were the most commonly prescribed class of medications, which may reflect the fact that the majority of patients had been hospitalized with fractures or for orthopedic procedures. While fractures were the commonest reason for hospitalization in patients admitted to the TCP, this was not mirrored by the use of anti-resorptives and vitamin D and analogues, which was lower than expected, given the importance of these medications in the prevention of osteoporotic fractures.[@b34-cia-9-1453],[@b35-cia-9-1453]

Though analgesic use was high, no patients were prescribed potent non-steroidal anti-inflamatory drugs, which are listed as PIMs under the Beers Criteria,[@b25-cia-9-1453] due to greater propensity for gastrointestinal side effects. The majority of PIMs that met Beers criteria were not prescribed for any of the patients in our study.

The difficulties comparing our study with other published polypharmacy studies, due to different patient selection and polypharmacy definitions, are acknowledged. Our study has prospectively collected data on functional outcomes in a cohort of patients often excluded from clinical studies -- frail elderly patients residing in the community but meeting criteria for residential aged care. This is an important group of patients in which interventions can delay or avoid institutionalization.[@b17-cia-9-1453] Considerations should be given to enabling regular medication reviews and rationalization in patients enrolled in community rehabilitation and Transition Care Programs, by encouraging regular pharmacist and medical input. These interventions have been shown to improve appropriate prescribing and reduce drug-related adverse events, though results on number of medications prescribed have been variable.[@b6-cia-9-1453],[@b36-cia-9-1453]--[@b39-cia-9-1453]

The strengths of our study are that the cohort is characteristic of older people eligible for post-discharge home-based care and representative of TCP recipients in particular, having been recruited across multiple sites in both rural and metropolitan communities. Few studies have explored associations of polypharmacy with functional outcomes after a period of longitudinal follow up. A study limitation is that the medication lists were documented by the interRAI assessors who transcribed or photocopied the patients' drug charts from hospital discharge summaries. It is acknowledged that this method of collecting medication data is not the current gold standard. To achieve complete medication reconciliation, multiple sources of information (including patient interview, general practitioner's letter, and dispensing history from the pharmacy) should be accessed. A further limitation is that the indications for each medication prescribed could not be determined.

Conclusion
==========

Polypharmacy is common in older patients discharged from hospital to home-based care. It is associated with frailty, falls, and poor functional outcomes. Efforts should be made to encourage regular medication reviews and rationalization of medications by pharmacists and geriatricians in these frail patients with reduced physiological reserves. Use of medications associated with functional decline such as benzodiazepines and anticholinergics as well as other PIMs should be minimized.

Supplementary material
======================

###### 

Potentially inappropriate medications Beers Criteria 2012

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Potentially inappropriate medications                                                                                                       ATC code for drug as a single agent   ATC code(s) for drug in combination with other agents
  ------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------- -------------------------------------------------------
  ***Anticholinergics***                                                                                                                                                            

  **Antihistamines** (as single agent or as part of combination products)                                                                                                           

  Brompheniramine                                                                                                                             R06AB01                               R06AB51

  Carbinoxamine                                                                                                                               R06AA08                               

  Chlorpheniramine                                                                                                                            R06AB04                               R06AB54

  Clemastine                                                                                                                                  R06AA04                               R06AA54

  Cyproheptadine                                                                                                                              R06AX02                               

  Dexbrompheniramine                                                                                                                          R06AB06                               R06AB56

  Dexchlorpheniramine                                                                                                                         R06AB02                               R06AB52

  Diphenhydramine (oral)                                                                                                                      R06AA02                               R06AA52

  Doxylamine                                                                                                                                  R06AA09                               R06AA59

  Hydroxyzine                                                                                                                                 N05BB01                               N05BB51

  Promethazine                                                                                                                                R06AD02                               R06AD52

  Triprolidine                                                                                                                                R06AX07                               

  **Antiparkinson agents**                                                                                                                                                          

  Benztropine (oral)                                                                                                                          N04AC01                               

  Trihexyphenidyl                                                                                                                             N04AA01                               

  ***Antithrombotics***                                                                                                                                                             

  Dipyridamole, oral short acting[\*](#tfn15-cia-9-1453){ref-type="table-fn"} (does not apply to extended release combination with aspirin)   B01AC07                               

  Ticlopidine[\*](#tfn15-cia-9-1453){ref-type="table-fn"}                                                                                     B01AC05                               

  **Anti-arrhythmics**                                                                                                                                                              

  Digoxin \>0.125 mg/d                                                                                                                        C01AA05                               

  **Tertiary TCAs, alone or in combination**                                                                                                                                        

  Amitriptyline                                                                                                                               N06AA09                               N06CA01

  Chlordiazepoxide-amitriptyline                                                                                                                                                    N06CA01

  Clomipramine                                                                                                                                N06AA04                               

  Doxepin \>6 mg/d                                                                                                                            N06AA12                               

  Imipramine                                                                                                                                  N06AA02                               N06AA03

  Perphenazine-amitriptyline                                                                                                                                                        N06CA01

  Trimipramine                                                                                                                                N06AA06                               

  **Barbiturates**                                                                                                                                                                  

  Amobarbital[\*](#tfn15-cia-9-1453){ref-type="table-fn"}                                                                                     N05CA02                               

  Butabarbital[\*](#tfn15-cia-9-1453){ref-type="table-fn"}                                                                                    None                                  

  Butalbital                                                                                                                                  None                                  

  Mephobarbital[\*](#tfn15-cia-9-1453){ref-type="table-fn"}                                                                                   N03AA01                               

  Pentobarbital[\*](#tfn15-cia-9-1453){ref-type="table-fn"}                                                                                   N05CA01                               

  Phenobarbital                                                                                                                               N03AA02                               

  Secobarbital[\*](#tfn15-cia-9-1453){ref-type="table-fn"}                                                                                    N05CA06                               

  Meprobamate                                                                                                                                 N05BC01                               N05BC51

  **Sulfonylureas, long duration**                                                                                                                                                  

  Chlorpropamide                                                                                                                              A10BB02                               

  Glyburide (glibenclamide)                                                                                                                   A10BB01                               

  ***Analgesics***                                                                                                                                                                  

  Meperidine                                                                                                                                  N02AB02                               

  Indomethacin                                                                                                                                M01AB01                               

  Ketorolac                                                                                                                                   M01AB15                               

  Pentazocine[\*](#tfn15-cia-9-1453){ref-type="table-fn"}                                                                                     N02AD01                               

  ***Antipsychotics***                                                                                                                                                              

  Thioridazine                                                                                                                                N05AC02                               

  Mesoridazine                                                                                                                                N05AC03                               

  Meprobamate                                                                                                                                 N05BC01                               N05BC51

  Ergot mesylates[\*](#tfn15-cia-9-1453){ref-type="table-fn"}                                                                                 C04AE51                               

  Isoxsuprine[\*](#tfn15-cia-9-1453){ref-type="table-fn"}                                                                                                                           

  **Endocrine**                                                                                                                                                                     

  Estrogens with or without progestins (oral and patch)                                                                                       G03                                   

  Megestrol                                                                                                                                   G03AC05 G03DB02 L02AB01               G03FA08 G03FB04\
                                                                                                                                                                                    G03AA04 G03AB01

  **Skeletal muscle relaxants**                                                                                                                                                     

  Carisoprodol                                                                                                                                M03BA02                               

  Chlorzoxazone                                                                                                                               M03BB03                               

  Cyclobenzaprine                                                                                                                             M03BX08                               

  Metaxalone                                                                                                                                  M03BX08                               

  Methocarbamol                                                                                                                               M03BA03                               

  Orphenadrine                                                                                                                                N04AB02                               M03BC01 M03BC51
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Infrequently used drugs.

**Abbreviations:** ATC, anatomical therapeutic chemical; TCA, tricyclic antidepressants.

The project was supported by the Australian National Health and Medical Research Council Health Services Research Program Grant (ID 402791) on Transition Care: Innovation and Evidence. The funding source had no involvement in the study.
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###### 

Characteristics of patients on admission to the TCP according to polypharmacy status

                                                                       All n=347     Non-polypharmacy \<5 drugs n=49 (14.1%)   Polypharmacy 5--9 drugs n=162 (46.7%)   Hyperpolypharmacy ≥10 drugs n=136 (39.2%)   *P*-value
  -------------------------------------------------------------------- ------------- ----------------------------------------- --------------------------------------- ------------------------------------------- -----------
  **Demographics**                                                                                                                                                                                                 
  Age, mean ± SD                                                       78.9±8.8      78.7±9.6                                  78.5±8.6                                79.4±8.7                                    0.696
  Female                                                               228 (65.7)    30 (61.2)                                 104 (64.2)                              94 (69.1)                                   0.521
  **Medications**                                                                                                                                                                                                  
  Regular, mean ± SD                                                   8.5±3.6       2.8±1.2                                   7.2±1.3                                 12.2±2.0                                    \<0.001
  PRN, mean ± SD                                                       0.8±1.1       0.9±1.1                                   0.7±0.9                                 0.9±1.2                                     0.341
  **Comorbidities**                                                                                                                                                                                                
  No of comorbidities, mean ± SD                                       6.0±3.0       3.9±2.5                                   5.8±2.7                                 7.0±3.1                                     \<0.001
  Diabetes                                                             89 (26.3)     6 (12.8)                                  39 (25.2)                               44 (32.4)                                   0.029
  Coronary heart disease                                               116 (34.1)    7 (14.9)                                  57 (35.8)                               52 (38.8)                                   0.010
  COPD                                                                 44 (13.1)     2 (4.3)                                   15 (9.7)                                27 (20.1)                                   0.006
  Depression                                                           72 (21.4)     3 (6.4)                                   38 (24.5)                               31 (23.0)                                   0.015
  **Symptoms**                                                                                                                                                                                                     
  Pain -- moderate/severe                                              179 (52.0)    24 (50.0)                                 69 (43.1)                               86 (63.2)                                   0.002
  Dizziness                                                            84 (24.5)     8 (16.7)                                  30 (18.9)                               46 (33.8)                                   0.005
  Dyspnea                                                              132 (38.3)    9 (18.8)                                  62 (38.5)                               61 (44.9)                                   0.006
  Fatigue -- moderate/severe                                           148 (42.9)    19 (40.4)                                 65 (40.1)                               64 (47.1)                                   0.452
  Constipation                                                         65 (18.8)     7 (14.6)                                  28 (17.4)                               30 (22.1)                                   0.425
  **Geriatric syndromes and frailty status**                                                                                                                                                                       
  Falls in previous 90 days                                            201 (58.6)    25 (52.1)                                 97 (61.0)                               79 (58.1)                                   0.539
  Cognition impaired[a](#tfn2-cia-9-1453){ref-type="table-fn"}         102 (29.8)    14 (29.2)                                 54 (34.2)                               34 (25.0)                                   0.228
  ADL scale,[b](#tfn3-cia-9-1453){ref-type="table-fn"} median (IQR)    3 (1--6)      3 (0--7.5)                                3 (1--6)                                4 (1--6)                                    0.588
  IADL scale,[c](#tfn4-cia-9-1453){ref-type="table-fn"} median (IQR)   25 (19--31)   25.5 (19.25--29.75)                       25 (18.5--32)                           26 (19--31)                                 0.813
  Daily bladder incontinence                                           46 (13.3)     7 (14.3)                                  20 (12.3)                               19 (14.0)                                   0.895
  Frailty index, mean ± SD                                             0.30±0.12     0.25±0.10                                 0.30±0.11                               0.33±0.11                                   \<0.001

**Notes:** Unless otherwise stated, columns represent n (%).

Based on the CPS, which ranges from 0 (intact cognition) to 6 (very severe cognitive impairment);[@b21-cia-9-1453] cognitively impaired patients were defined as CPS scores ≥2, corresponding to a mean Mini Mental State Examination score of \<24.[@b21-cia-9-1453]

Based on ADL scale (long form), which assesses independence in seven ADL items (personal hygiene, dressing upper body and lower body, locomotion, toilet use, bed mobility, and eating). The scale has a range from 0 to 28, with higher scores indicating greater dependence.[@b17-cia-9-1453]

The IADL scale summarizes the performance on seven IADL items (meal preparation, housework, finances, medication management, phone use, shopping, and transport). The scale has a range from 0 to 42, with higher scores indicating greater dependence.[@b17-cia-9-1453]

**Abbreviations:** ADL, activities of daily living; COPD, chronic obstructive pulmonary disease; CPS, cognitive performance scale; IADL, instrumental ADL; IQR, interquartile range; PRN, pro re nata; SD, standard deviation; TCP, Transition Care Program.

###### 

Outcomes at discharge from the TCP according to polypharmacy status

                                                                         All n=347     Non-polypharmacy \<5 drugs n=49 (14.1%)   Polypharmacy 5--9 drugs n=162 (46.7%)   Hyperpolypharmacy ≥10 drugs n=136 (39.2%)   *P*-value
  ---------------------------------------------------------------------- ------------- ----------------------------------------- --------------------------------------- ------------------------------------------- -----------
  Discharge destination                                                                0.200                                                                                                                         
   -- Community                                                          297 (85.6)    44 (89.8)                                 139 (85.8)                              114 (83.8)                                  
   -- Hospital                                                           43 (12.4)     3 (6.1)                                   20 (12.3)                               20 (14.7)                                   
   -- RACF                                                               3 (0.9)       2 (4.1)                                   1 (0.6)                                 0 (0.0)                                     
   -- Died                                                               4 (1.2)       0 (0.0)                                   2 (1.2)                                 2 (1.5)                                     
  Length of stay (days) median (IQR)                                     54 (37--73)   57 (38.5--80)                             54 (38.75--69.25)                       48.5 (31.25--73)                            0.199
  Failure to improve in ADL[a](#tfn7-cia-9-1453){ref-type="table-fn"}    42 (12.6)     2 (4.1)                                   15 (9.8)                                25 (18.9)                                   0.011
  Failure to improve in IADL[b](#tfn8-cia-9-1453){ref-type="table-fn"}   63 (19.0)     4 (8.3)                                   23 (14.9)                               36 (27.7)                                   0.003
  Falls while in the TCP                                                 48 (15.3)     2 (4.5)                                   30 (20.4)                               16 (13.0)                                   0.023

**Notes:** Unless otherwise stated, columns represent n (%).

Failure to improve in ADL was defined as having a worse (higher) ADL scale score at discharge than at admission or maintaining their score for those with some impairment on admission.[@b17-cia-9-1453]

Failure to improve in IADL was defined as having a worse (higher) IADL scale score at discharge than at admission or maintaining their score for those with some impairment on admission.[@b17-cia-9-1453]

**Abbreviations:** ADL, activities of daily living; IADL, instrumental ADL; IQR, interquartile range; RACF, residential aged care facilities; TCP, Transition Care Program.

###### 

Logistic regression modelling of functional outcomes at discharge from the TCP

  Covariates                                                        Failure to improve ADL OR (95% CI)                              Failure to improve IADL OR (95% CI)                              Falls OR (95% CI)
  ----------------------------------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------------- -----------------------------------------------------------------
  Medication use                                                                                                                                                                                     
   -- Non-polypharmacy[a](#tfn10-cia-9-1453){ref-type="table-fn"}   1                                                               1                                                                1
   -- Polypharmacy                                                  2.22 (0.48--10.16)                                              1.68 (0.55--5.19)                                                4.69 (1.06--20.68)[\*](#tfn11-cia-9-1453){ref-type="table-fn"}
   -- Hyperpolypharmacy                                             4.33 (0.97--19.42)                                              3.42 (1.13--10.38)[\*](#tfn11-cia-9-1453){ref-type="table-fn"}   2.34 (0.50--10.84)
  Frailty index                                                     1.38 (1.01--1.87)[\*](#tfn11-cia-9-1453){ref-type="table-fn"}   1.36 (1.04--1.77)[\*](#tfn11-cia-9-1453){ref-type="table-fn"}    1.50 (1.12--2.01)[\*\*](#tfn12-cia-9-1453){ref-type="table-fn"}

**Notes:**

Reference category.

*P*\<0.05,

\*\**P*\<0.01.

**Abbreviations:** ADL, activities of daily living; IADL, instrumental ADL; CI, confidence interval; OR, odds ratio; TCP, Transition Care Program.

###### 

Prevalence of drug use in TCP patients by medication class

  Drug                                       All n=347    Non-polypharmacy \<5 drugs n=49 (14.1%)   Polypharmacy 5--9 drugs n=162 (46.7%)   Hyperpolypharmacy ≥10 drugs n=136 (39.2%)
  ------------------------------------------ ------------ ----------------------------------------- --------------------------------------- -------------------------------------------
  Analgesics                                 197 (58.6)   15 (30.6)                                 84 (51.9)                               98 (72.1)
   -- Non-opioids                            160 (46.1)   9 (18.4)                                  73 (45.1)                               78 (57.4)
   -- Opioids                                94 (27.1)    8 (16.3)                                  31 (19.1)                               55 (40.4)
  Antiulcer                                  183 (52.7)   12 (24.5)                                 80 (49.4)                               91 (66.9)
  Statins                                    153 (44.1)   11 (22.4)                                 64 (39.5)                               78 (57.4)
  Aspirin and anti-aggregates                150 (43.2)   9 (18.4)                                  64 (39.5)                               77 (56.6)
  Beta blockers                              119 (34.3)   7 (14.3)                                  53 (32.7)                               59 (43.4)
  Angiotensin converting enzyme inhibitors   109 (31.4)   9 (18.4)                                  47 (29.0)                               53 (39.0)
  Antidepressants                            107 (30.8)   1 (2.0)                                   51 (31.5)                               55 (40.4)
   -- Tricyclics                             33 (9.5)     1 (2.0)                                   13 (8.0)                                19 (14.0)
   -- SSRIs                                  47 (13.5)    0 (0.0)                                   23 (14.2)                               24 (17.6)
   -- MAO inhibitors                         1 (0.3)      0 (0.0)                                   1 (0.6)                                 0 (0.0)
   -- Other (eg, SNRIs)                      30 (8.6)     0 (0.0)                                   15 (9.3)                                15 (11.0)
  Laxatives                                  97 (28.0)    6 (12.2)                                  32 (19.8)                               59 (43.4)
  Vitamin D and analogues                    94 (27.1)    3 (6.1)                                   41 (25.3)                               50 (36.8)
  Diuretics                                  94 (27.1)    3 (6.1)                                   35 (21.6)                               56 (41.2)
  Calcium channel blockers                   90 (25.90)   3 (6.1)                                   39 (24.1)                               48 (35.3)
  Calcium                                    85 (24.5)    3 (6.1)                                   36 (22.2)                               46 (33.8)
  Angiotensin receptor blockers              78 (22.5)    2 (4.1)                                   42 (25.9)                               34 (25.0)
  Osteoporosis/anti-resorptives              78 (22.5)    4 (8.2)                                   31 (19.1)                               43 (31.6)
  Anticoagulants                             59 (17.0)    7 (14.3)                                  32 (19.8)                               20 (14.7)
   -- Heparin                                15 (4.3)     3 (6.1)                                   7 (4.3)                                 5 (3.7)
   -- Warfarin                               46 (13.3)    4 (8.2)                                   26 (16.6)                               16 (11.7)
  Oral hypoglycemics                         57 (16.4)    4 (8.2)                                   25 (15.4)                               28 (20.6)
  Eye medications                            50 (14.4)    2 (4.1)                                   17 (10.5)                               31 (22.8)
  Thyroid medications                        48 (13.8)    3 (6.1)                                   14 (8.6)                                31 (22.8)
  COPD/asthma medications                    48 (13.8)    1 (2.0)                                   16 (9.9)                                31 (22.8)
  Corticosteroids                            46 (13.3)    1 (2.2)                                   16 (9.9)                                29 (21.3)
  Benzodiazepines                            44 (12.7)    3 (6.1)                                   12 (27.3)                               29 (21.3)
  Antibacterials                             44 (12.7)    1 (2.0)                                   18 (11.1)                               25 (18.4)
  Nitrates                                   37 (10.7)    0 (0.0)                                   10 (6.2)                                27 (19.9)
  Digoxin                                    30 (8.6)     1 (2.0)                                   10 (6.2)                                19 (14.0)
  Insulin                                    20 (5.8)     0 (0.0)                                   3 (1.9)                                 17 (12.5)
  Anti-emetics                               15 (4.3)     1 (2.0)                                   5 (3.1)                                 9 (6.6)
  Anti-Parkinson                             12 (3.5)     2 (4.1)                                   4 (2.5)                                 6 (4.4)
  Antipsychotics                             9 (2.6)      1 (2.0)                                   5 (3.1)                                 3 (2.2)
  Anti-dementia drugs                        4 (1.2)      0 (0.0)                                   3 (1.9)                                 1 (0.7)

**Abbreviations:** COPD, chronic obstructive pulmonary disease; MAO, monoamine oxidase; SNRI, serotonin norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCP, Transition Care Program.
